Research facility · founded 2012
Institute for Molecular Medicine
Huntington Beach, United States · immed.org
- Citations, last 5 years
- 263
- Works, last 5 years
- 46
- h-index
- 83
- Scientists listed
- 5
- Grants since 2016
- 22
Grants received
2025–2030 · research · R01
FDA approved IND 29644: Multicenter Phase 1 Trial to Evaluate Safety and Immunogenicity of Preventive Tau Vaccine, AV-1980R/A, in cognitively unimpaired preclinical AD participants.
Michael G Agadjanyan · Institute for Molecular Medicine · funded by National Institutes of Health
2024–2029 · cooperative agreement · U01
IND enabling CMC/safety/toxicology studies, submission of IND and pilot Phase 1 clinical trial with PV-1950R vaccine for Lewy Body Dementia (LBD)
Michael G Agadjanyan · Institute for Molecular Medicine · funded by National Institutes of Health
2024–2029 · cooperative agreement · U01
IND enabling CMC/safety/toxicology studies, submission of IND and pilot Phase 1 clinical trial with PV-1950R vaccine for Lewy Body Dementia (LBD)
Michael G Agadjanyan · Institute for Molecular Medicine · funded by National Institutes of Health
2022–2027 · research · R01
Manufacturing of New Batch AV-1959D Drug Product and Placebo for Phase 1 Trial
Michael G Agadjanyan · Institute for Molecular Medicine · funded by National Institutes of Health
2022–2027 · research · R01
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.
Michael G Agadjanyan · Institute for Molecular Medicine · funded by National Institutes of Health
2022–2027 · research · R01
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.
Michael G Agadjanyan · Institute for Molecular Medicine · funded by National Institutes of Health
2022–2027 · research · R01
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.
Michael G Agadjanyan · Institute for Molecular Medicine · funded by National Institutes of Health
2022–2027 · research · R01
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.
Michael G Agadjanyan · Institute for Molecular Medicine · funded by National Institutes of Health
2019–2025 · cooperative agreement · U01
Cooperative program U01 AG060965 Supplement: "Preparation of IND for Dual Aβ/Tau AD Vaccine for submission to FDA"
Michael G Agadjanyan · Institute for Molecular Medicine · funded by National Institutes of Health
2019–2025 · cooperative agreement · U01
IND-enabling Preclinical Studies on Anti-Tau AD Vaccine for Phase 1 Trial
Michael G Agadjanyan · Institute for Molecular Medicine · funded by National Institutes of Health
2019–2023 · cooperative agreement · U01
IND-enabling Preclinical Studies on Anti-Tau AD Vaccine for Phase 1 Trial
Michael G Agadjanyan · Institute for Molecular Medicine · funded by National Institutes of Health
2019–2023 · cooperative agreement · U01
IND-enabling Preclinical Studies for Aβ and Dual Aβ/Tau MultiTEP platform-based AD Vaccines
Michael G Agadjanyan · Institute for Molecular Medicine · funded by National Institutes of Health
2019–2023 · cooperative agreement · U01
Evaluation of Safe and Immunogenic Dose of AD Vaccine in aged non-human primates: Prelude to Phase 1 Preventive Vaccinations
Michael G Agadjanyan · Institute for Molecular Medicine · funded by National Institutes of Health
2019–2022 · cooperative agreement · U01
Repurposing of Universal and Immunogenic MultiTEP Platform Designed for AD to Develop SARS-CoV-2 Multiepitope Vaccine
Michael G Agadjanyan · Institute for Molecular Medicine · funded by National Institutes of Health
2019–2023 · cooperative agreement · U01
IND-enabling Preclinical Studies on Anti-Tau AD Vaccine for Phase 1 Trial
Michael G Agadjanyan · Institute for Molecular Medicine · funded by National Institutes of Health
2019–2025 · cooperative agreement · U01
Manufacturing of Drug Product, Dual Aβ/tau Vaccine for Clinical Trials
Michael G Agadjanyan · Institute for Molecular Medicine · funded by National Institutes of Health
2019–2023 · cooperative agreement · U01
IND-enabling Preclinical Studies on Anti-Tau AD Vaccine for Phase 1 Trial
Michael G Agadjanyan · Institute for Molecular Medicine · funded by National Institutes of Health
2017–2019 · research · R01
Combining AD Epitope Vaccine with Innate Immunity
Michael G Agadjanyan · Institute for Molecular Medicine · funded by National Institutes of Health
2017–2020 · research · R21
The Dimer Specific Anti-Amyloid-β Vaccine Based on the Nanoarray Assembly
Anahit Ghochikyan · Institute for Molecular Medicine · funded by National Institutes of Health
2017–2019 · research · R21
The Dimer Specific Anti-Amyloid-β Vaccine Based on the Nanoarray Assembly
Anahit Ghochikyan · Institute for Molecular Medicine · funded by National Institutes of Health
2004–2020 · research · R01
Combining AD Epitope Vaccine with Innate Immunity
Michael G Agadjanyan · Institute for Molecular Medicine · funded by National Institutes of Health
2001–2023 · research · RF1
Multiple Approaches to Abeta Vaccination in Animal Models
Michael G Agadjanyan · Institute for Molecular Medicine · funded by National Institutes of Health